The Future of Temperature-Controlled Technology

In a video interview with Pharma Commerce, Delphine Perridy, chief commercial officer, Envirotainer, noted that the pharmaceutical industry is undergoing significant evolution driven by unmet patient needs, rapid scientific advancements, and the emergence of new technologies. Innovations such as gene therapies, precision medicines, and advancements in obesity treatment with GLP-1s exemplify this shift. Additionally, the integration of artificial intelligence in drug discovery is streamlining research and development processes, lowering costs, and accelerating time to market. As a result, pharmaceutical companies must adapt their business models to ensure that newly approved drugs reach patients worldwide more efficiently. Perridy also shared why ultra-precise temperature control and customized logistics solutions are so critical when it comes to biologics and personalized medicine; why has the demand for sustainable practices has risen exponentially; Where she believes the pharma cold chain is heading in the next few years in terms of technological breakthroughs and market dynamic shifts.

A transcript of Perridy’s conversation with PC can be found below.

PC: Where do you believe the pharma cold chain is heading in the next few years in terms of technological breakthroughs and market dynamic shifts?

Perridy: We're going to continue to see an increase in personalized medicine, cell & gene therapies, and much more complex treatments that are going to require strict requirements when it comes to cold chain solutions. That's clearly the first shift that I think we're going to continue seeing.

The second one will be the use of AI more and more in the industry. I think that we're going to be able to use artificial intelligence to do much more analysis in terms of trade lane analysis or risk management overall. I think that the second shift that we're going to see coming over the next couple of years is sustainability—it’s going to remain a topic that is not going anywhere. I think it's an important topic for the society. We can expect to get much more pressure when it comes to sustainability—it's going to be very important for us to really design packaging solutions that can be more sustainable moving forward.

The last one is the geopolitics risk; it’s also something that is probably meant to continue. I think it's very important that we work with our partners to come up with very strong logistics strategies so that we can keep pharma moving, regardless of the challenges that we are facing. We need to build resilient networks so that we can adapt quickly and continue shipping medicines wherever they need to be shipped.